[1]naphthylmethyl-phenethyl-amine | 872796-69-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: [1]naphthylmethyl-phenethyl-amine
• 英文别名: [1]Naphthylmethyl-phenaethyl-amin；N-(naphthalen-1-ylmethyl)-2-phenylethanamine
• CAS: 872796-69-5
• 化学式: C₁₉H₁₉N
• 分子量: 261.367
• InChiKey: CVKSLLNYWREMPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 [1]naphthylmethyl-phenethyl-amine 在 甲酸 、 水 作用下， 生成 N-methyl-N-(2-phenylethyl)-1-naphthalenemethanamine
  参考文献：
  名称：

  Rylski, Acta Poloniae Pharmaceutica, 1958, vol. 15, p. 217

  摘要：

  DOI：
• 作为产物：
  描述：

  [1]naphthylmethylene-phenethyl-amine 在 palladium on activated charcoal 作用下， 生成 [1]naphthylmethyl-phenethyl-amine
  参考文献：
  名称：

  Biniecki et al., Annales Pharmaceutiques Francaises, 1955, vol. 13, p. 249,251

  摘要：

  DOI：

文献信息

• CALCIUM RECEPTOR-ACTIVE MOLECULES
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US20130190407A1

  公开（公告）日：2013-07-25

  The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca 2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.

  本发明涉及无机离子受体在细胞和身体过程中的不同作用。 本发明的特点包括：（1）分子可以调节一个或多个无机离子受体的活性，最好是分子可以模拟或阻断细胞上的无机离子受体对细胞外离子的影响，更好的是细胞外离子是Ca2 +，其影响是在具有钙受体的细胞上; （2）无机离子受体蛋白及其片段，最好是钙受体蛋白及其片段; （3）编码无机离子受体蛋白及其片段的核酸，最好是编码钙受体蛋白及其片段的核酸; （4）针对无机离子受体蛋白的抗体及其片段，最好是钙受体蛋白; 以及（5）使用这些分子，蛋白质，核酸和抗体。
• Rylski, Acta Poloniae Pharmaceutica, 1958, vol. 15, p. 217
  作者：Rylski

  DOI：——

  日期：——
• Biniecki; Rylski, Acta Poloniae Pharmaceutica, 1954, vol. 11, p. 9,17
  作者：Biniecki、Rylski

  DOI：——

  日期：——
• Biniecki et al., Annales Pharmaceutiques Francaises, 1955, vol. 13, p. 249,251
  作者：Biniecki et al.

  DOI：——

  日期：——
• Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics
  作者：Anton Stuetz、Apostolos Georgopoulos、Waltraud Granitzer、Gabor Petranyi、Daniel Berney

  DOI：10.1021/jm00151a019

  日期：1986.1

  Naftifine (1) is the first representative of the new antifungal allylamine derivatives. Its biological activity is strictly bound to specific structural requirements that are unrelated to those of known antifungals. A tertiary allylamine function seems to be a prerequisite for activity against fungi. By systematic variation of the individual structural elements in 1, detailed structure-activity relationships are defined in which the phenyl ring is the structural feature permitting the widest variations. Versatile synthetic routes to allylamine derivatives and comparative biological data are presented.